Vyvgart Iv MG denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for vyvgart iv mg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Vyvgart IV for Myasthenia Gravis as Duplicate Therapy

Vyvgart (efgartigimod alfa, intravenous formulation) is FDA-approved for generalized myasthenia gravis (gMG) in adults who are anti-AChR antibody positive. UnitedHealthcare may issue a duplicate-therapy denial when the patient is also receiving another agent that the plan believes covers the same mechanism or clinical purpose — commonly another FcRn inhibitor, a complement inhibitor, or another biologic approved for gMG. The plan's argument is that two therapies targeting the same condition simultaneously are redundant.

## Why This Denial Is Appealable

A duplicate-therapy denial is appealable when the clinical record demonstrates that the two therapies work through distinct mechanisms, that the combination is consistent with recognized neuromuscular disease management principles, or that one therapy is being used as a bridge or transition while the other is being discontinued. The prescribing neurologist's clinical rationale is the centerpiece of this appeal.

## Federal Appeal Framework

• Internal appeal: Under ACA §2719 and ERISA §503, you are entitled to a full-and-fair review. Submit with a clinical explanation of why both therapies are necessary simultaneously (or why the alleged duplicate is actually serving a different clinical role).
• Peer-to-peer review: Request one immediately — this denial type often turns on a clinical conversation between the prescribing neurologist and the UHC reviewing physician.
• External review: If the internal appeal fails, escalate to independent external review within the window on the denial notice (commonly around four months from the final internal denial).
• Expedited review: Available when delay would cause serious health jeopardy — gMG exacerbations can be life-threatening, so expedited review is often appropriate.

## Documentation to Gather

1. Diagnosis and disease-severity documentation — chart records confirming generalized MG, antibody status, and current functional severity. 2. Rationale for concurrent therapies — the neurologist's clinical notes explaining why both agents are being used, their distinct roles in the treatment plan, and the planned duration of any overlap. 3. Mechanism-of-action explanation — a brief prescriber statement or published reference explaining the distinct mechanisms of each agent, if the plan's reviewers appear to be conflating them. 4. Transition or tapering plan — if one agent is being phased out, document the timeline and rationale. 5. UHC coverage policy — download the current UHC medical policy for Vyvgart IV to identify the exact duplicate-therapy criteria being applied.

## Criteria-Mapping Structure

Address each element of the UHC duplicate-therapy criterion from the current published policy. For each criterion, provide a chart-based response explaining how this patient's situation does not constitute duplication — or, if there is genuine overlap, the clinical justification for it. Consult the FDA prescribing label and UHC's current coverage policy for exact language; do not rely on recalled policy versions.